Aug 27, 2020Health Sciences0 likes Auto-indexed

BATTLING COVID-19: INSTITUT KANSER NEGARA COVID-19 TASK FORCE STRATEGIES

Keywords:COVID-19BattlingInstitut Kanser NegaraCoronavirusTask Force StrategiesTaskforce
Poster thumbnail

Description

Introduction Even today, the coronavirus disease 2019 (COVID-19) continues to profoundly impact healthcare systems worldwide. This is especially significant in cancer care, where patients are not only more susceptible to being infected and developing complications from COVID-19, 1,2 but also face the risk of disease progression should treatment pathways be disrupted. Being the national oncology referral centre, Institut Kanser Negara (IKN) developed its own multidisciplinary task force in curbing the spread of COVID-19, which this study aims to describe. Methodology A retrospective descriptive study design was used to report strategies and impact of the COVID-19 task force in IKN from March to May 2020. Results There was a partial disruption of clinical services as many healthcare workers (HCWs) were quarantined due to four positive COVID-19 cases among IKN HCWs. In spite of this unprecedented situation, patient care was not compromised as all available resources were fully utilized and temporary assistance was received from the Department of Radiotherapy and Oncology, Hospital Kuala Lumpur to ensure the continuity of services. Figure 1 depicts the strategies implemented in IKN in line with the Movement Control Order (MCO) phases in Malaysia. Discussion / Conclusion To date, there is no staff-to-patient transmission documented in IKN, which proved the effectiveness of strategies implemented through the task force. SARS-CoV-2 is a highly infectious pathogen which led to overwhelming consequences globally. With continuous awareness, stringent infection control protocols as well as new normal practices, we hope to ensure a safe environment in IKN without compromising patient care.

Conference Information

H-06

Year:2020
Location:Malaysia
Dates:Mar 1 - May 31, 2020

Identifiers

Authors

Sarah Hui Li Pang

Clinical Research Centre, Institut Kanser Negara, Ministry of Health, Malaysia

Siti Fatimah Zahra Mohd Anuar

Clinical Research Centre, Institut Kanser Negara, Ministry of Health, Malaysia

Kosholah Balakrishnaa

Clinical Research Centre, Institut Kanser Negara, Ministry of Health, Malaysia

Nur Adila Che Rameli

Quality Assurance Unit, Institut Kanser Negara, Ministry of Health Malaysia

Sri Devi Ayavoo

Quality Assurance Unit, Institut Kanser Negara, Ministry of Health Malaysia

Sarah Aqilah Ghazali

Clinical Research Centre, Institut Kanser Negara, Ministry of Health, Malaysia

Melvyn Yin Chung Chin

Clinical Research Centre, Institut Kanser Negara, Ministry of Health, Malaysia

Yoke Fui Wong

Clinical Research Centre, Institut Kanser Negara, Ministry of Health, Malaysia

Additional Information

LanguageEnglish
Formatapplication/pdf
Version1
License
Creative Commons Attribution 4.0 International
Indexed fromZenodo